Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT07733050 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Serplulimab and Bevacizumab injection
DRUG: FOLFIRINOX/NALIRIFOX
DRUG: S-1

Sponsor

Shanghai General Hospital, China